FDA Approves Once-a-Month Dose of Actonel
Posted on: Friday, 25 April 2008, 03:00 CDT
The Alliance for Better Bone Health, a collaboration between Procter & Gamble Pharmaceuticals and Sanofi-Aventis US, has announced that FDA has approved a new once-a-month dose of Actonel tablets for the treatment and prevention of postmenopausal osteoporosis.
Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.
The FDA approval of the once-a-month dose is based on a study comparing Actonel 150mg once monthly to Actonel 5mg daily. Similar increases in bone mineral density (BMD) were seen among patients under once-a-month or daily dosing regimens.
Source: Datamonitor
Related Articles
- Affymax Announces New Data Presented on the Long-Term Safety and Effectiveness of Hematide(TM) to Treat Anemia in Chronic Renal Failure Patients With Monthly Dosing
- Affymax(R) Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide(TM) for the Treatment of Anemia
- Monthly Psychotherapy Helps Depression
- Affymax(R) Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide(TM) for the Treatment of Anemia in Patients With Early- and End-Stage Chronic Kidney Disease
- First X-Ray of a Colliding-Wind Binary
- U.S. Death Toll in Iraq This Month Hits 35
- Bryant ends high-scoring month leading Lakers past Knicks
- WIN Cash for Recyling
- SUPPER at SIMONE's IOWA
- Bush, Kerry Tentatively OK Three Debates
Rating: 5.0 / 5 (3 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds